Abstracts tagged "Antibodies"

Abstract Number: 2682 • 2016 ACR/ARHP Annual Meeting
How Does Primary Sjogren Syndrome Present in Biopsy-Proven Patients without Circulating Ro/La Autoantibodies? Characteristics at Diagnosis of 2073 Patients from the SjöGren Big Data Project
Pilar Brito-Zerón^1,2,3, Nihan Acar-Denizli⁴, Margit Zeher⁵, Astrid Rasmussen⁶, Raphaele Seror⁷, Elke Theander⁸, Xiaomei Li⁹, Chiara Baldini¹⁰, Jacques-Eric Gottenberg¹¹, Debashish Danda¹², Luca Quartuccio¹³, Roberta Priori^14,15, Gabriela Hernandez-Molina¹⁶, Aike A. Kruize¹⁷, Valeria Valim¹⁸, Marika Kvarnström¹⁹, Damien Sene²⁰, Roberto Gerli²¹, Sonja Praprotnik²², David A. Isenberg²³, Roser Solans²⁴, Maureen Rischmueller²⁵, Seung-Ki Kwok²⁶, Gunnel Nordmark²⁷, Yasunori Suzuki²⁸, Roberto Giacomelli²⁹, Valerie Devauchelle-Pensec³⁰, Michele Bombardieri³¹, Benedikt Hofauer³², Hendrika Bootsma³³, Johan G. Brun³⁴, Guadalupe Fraile³⁵, Steven E. Carsons³⁶, Tamer Gheita³⁷, Jacques Morel³⁸, Cristina F. Vollenweider³⁹, Fabiola Atzeni⁴⁰, Soledad Retamozo⁴¹, Ildike-Fanny Horvath⁵, Kathy Sivils⁶, Thomas Mandl^42,43, Pulukool Sandhya¹², Salvatore De Vita⁴⁴, Jorge Sánchez-Guerrero⁴⁵, Eefje van der Heijden¹⁷, Virginia Moça Trevisano⁴⁶, Marie Wahren-Herlenius¹⁹, Xavier Mariette⁷, Manuel Ramos-Casals^3,47,48 and EULAR-SS Task Force Big Data Consortium (ASSES, GEAS-SEMI, EULAR), ¹Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁴Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Turkey, Istabul, Turkey, ⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ⁷Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, Paris, France, ⁸Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Malmö, Sweden, ⁹Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, China, Hefei, Anhui, China, ¹⁰Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹¹Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France, ¹²Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ¹³Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, ¹⁴Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ¹⁵Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ¹⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ¹⁷Department of Rheumatology & Clinical Immunology, Medical Center Utrecht, The Netherlands, Utrecht, Netherlands, ¹⁸Rheumatology, Department of Medicine, Universidade Federal do Espírito Santo, Vitória, Brazil, Vitória, Brazil, ¹⁹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²⁰Service de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de Paris, 2, Paris, France, Paris, France, ²¹Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Italy, Perugia, Italy, ²²Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ²⁴Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ²⁵Department of Rheumatology, School of Medicine, The University of Western Australia, Crawley, Australia, Crawley, Australia, ²⁶[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²⁷Rheumatology, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ²⁸Division of Rheumatology , Kanazawa University Hospital , Kanazawa , Ishikawa , Japan, Ishikawa, Japan, ²⁹Clinical Unit of Rheumatology, University of l'Aquila, School of Medicine, L'Aquila, Italy, L'Aquila, Italy, ³⁰Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ³¹Willian Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, QMUL, UK, London, United Kingdom, ³²Hals-Nasen-Ohrenklinik und Poliklinik, Technische Universität München, München, Germany, München, Germany, ³³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands, ³⁴Department of Clinical Science, University of Bergen. Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, Bergen, Norway, ³⁵Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, ³⁶Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY, ³⁷Rheumatology, Rheumatology Department, Faculty of Medicine, Cairo University, Egypt, Cairo, Egypt, ³⁸Department of Rheumatology, Teaching hospital and University of Montpellier, France, Montpellier, France, ³⁹Rheumatology, German Hospital, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴⁰IRCCS Galeazzi Orthopedic Institute, Milan, Italy, Milan, Italy, ⁴¹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ⁴²Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, ⁴³Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Lund, Sweden, ⁴⁴Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy, Udine, Italy, ⁴⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ⁴⁶Federal University of São Paulo, Sao Paulo, Brazil, San Paulo, Brazil, ⁴⁷Sjögren Syndrome Research Group (AGAUR), Barcelona, Spain, ⁴⁸Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain
Background/Purpose: To analyse the main characteristics of patients with primary Sjögren syndrome (SjS) with focal lymphocytic sialadenitis (FLS) unrelated to the presence of circulating anti-Ro/La…
Abstract Number: 591 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
Louis Bessette¹, Majed Khraishi², Alan J Kivitz³, Arunan Kaliyaperumal⁴, Rama Grantab⁵, Melanie Poulin-Costello⁵, Maya Isaila⁵ and David Collier⁴, ¹Rhumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ²Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Amgen Canada Inc., Mississauga, ON, Canada
Background/Purpose: When a tumor necrosis factor inhibitor (TNFi) fails in a patient with moderate to severe rheumatoid arthritis (RA), new American College of Rheumatology (ACR)…
Abstract Number: 2687 • 2016 ACR/ARHP Annual Meeting
Prevalence of Abortions and Fetal Atrioventricular Block in Patients with Positive ANTI-RO and ANTI-La Antibodies
Isabel Martinez Cordellat¹, Francisco Miguel Ortiz-Sanjuán¹, Jose Ivorra Cortes¹, Luis Gonzalez Puig¹, Inmaculada Chalmeta Verdejo¹, Irene Calabuig Sais², Elena Grau Garcia^1,3, Carlos Feced Olmos¹, Eztizen Labrador Sanchez¹, Karla Arevalo Ruales¹, Rosa Negueroles Albuixech¹, Jorge Fragio Gil¹, Jose Luis Valero Sanz¹, Cristina Alcañiz Escandell^1,3, Carmen Najera Herranz¹, Gema Poveda Marin^1,3 and Jose Andres Roman Ivorra^1,2,3, ¹Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Universidad Católica de Valencia, Valencia, Spain, ³IIS La Fe, Valencia, Spain
Background/Purpose: anti-SSA/Ro and/or anti-SSB/La antibodies and to evaluate the prevalence of abortions and neonatal mortality. We included 162 patients with positive anti-SSA/Ro and/or…
Abstract Number: 613 • 2016 ACR/ARHP Annual Meeting
Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients
Alejandro Balsa¹, Raimon Sanmarti², José Rosas³, Susana Gomez Castro⁴, Ana Cabez⁴, Victor Martin⁴ and María Montoro⁴, ¹Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴Pfizer, Madrid, Spain
Abstract Immunogenicity of anti-TNF therapies in Patients with inflammatory rheumatic Diseases and secondary failure: a multicentre study of 570 patients. Background/Purpose: The treatment of…
Abstract Number: 2826 • 2016 ACR/ARHP Annual Meeting
Clinical Utility of Circulating Anti-N-Methyl-D-Aspartate Receptor Subunits NR2A/B Antibody for the Diagnosis of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Sjogren’s Syndrome: An Updated Meta-Analysis
Sen Hee Tay¹, Anna-Marie Fairhurst² and Anselm Mak¹, ¹Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, Singapore, ²Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore
Background/Purpose: Neuropsychiatric (NP) events are found in patients with rheumatic diseases, commonly in systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). The standard nomenclature and…
Abstract Number: 647 • 2016 ACR/ARHP Annual Meeting
Genomic and Epigenetic Bioinformatics Demonstrate Dual TNF-α and IL17A Target Engagement By ABT-122, and Suggest Mainly TNF-α–Mediated Relative Target Contribution to Drug Response in MTX-IR Rheumatoid Arthritis Patients
Robert W. Georgantas III¹, Melanie Ruzek², Justin Wade Davis¹, Feng Hong¹, Elizabeth Asque¹, Kenneth Idler¹, Heikki T. Mansikka¹, Benoit Guerette¹ and Jeffrey F. Waring¹, ¹AbbVie Inc., North Chicago, IL, ²Immunology Discovery, AbbVie, Worcester, MA
Background/Purpose: ABT-122 is a dual variable domain (DVD-Ig) biologic which inhibits TNF-α and IL17A. In a 12-wk phase 2 study (NCT02141997) in MTX-IR patients (pts)…
Abstract Number: 2841 • 2016 ACR/ARHP Annual Meeting
Anti-Ro52/TRIM21 Antibodies Are Associated with QT Interval Prolongation in Patients with Systemic Lupus Erythematosus
Luis F. Perez-Garcia¹, Irving Omar Estevez-Garcia¹, Mariana Moreno Ramirez¹, Javier Loaiza Felix¹, Ricardo Marquez-Velasco², Pedro Iturralde³, Luis H. Silveira^4,5 and Luis M. Amezcua-Guerra¹, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Cardiology - Electrophysiology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁴Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ⁵Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico
Background/Purpose: Long QT syndrome (LQTS) is characterized by an abnormal QT corrected (QTc) interval prolongation that is associated with increased risk of sudden death. Studies…
Abstract Number: 650 • 2016 ACR/ARHP Annual Meeting
ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Mark C. Genovese¹, Michael Weinblatt², Jacob A Aelion³, Heikki T. Mansikka⁴, Paul M. Peloso⁴, Kun Chen⁴, Yihan Li⁴, Ahmed A. Othman⁴, Amit Khatri⁴, Nasser S. Khan⁴ and Robert J. Padley⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Brigham and Women’s Hospital, Boston, MA, ³West Tennessee Research Institute, Jackson, TN, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Tumor necrosis factor (TNF) and interleukin 17 (IL-17) appear to independently contribute to the pathophysiology of rheumatoid arthritis (RA), synergistically inducing inflammatory mediators leading…
Abstract Number: 2875 • 2016 ACR/ARHP Annual Meeting
Depressed Serum IgM Levels in SLE Are Restricted to Defined Subgroups
Caroline Grönwall¹, Uta Hardt¹, Iva Gunnarsson², Gregg J. Silverman³ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Department of Medicine, Unit of Rheumatology, Stockholm, Sweden, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Natural IgM autoantibodies have been proposed to have protective properties, and decreased levels of IgM to phosphorylcholine (PC) in SLE are associated with higher…
Abstract Number: 726 • 2016 ACR/ARHP Annual Meeting
Comparison of Infliximab Immunogenicity in Inflammatory Arthritis Versus Inflammatory Bowel Disease Patients in Routine Clinical Practice
Marianne Guirgis¹, Melanie Favre dit Jeanfavre², Charles Benaim³, Matthieu Perreau⁴, Pierre Michetti⁵, Michel Maillard¹ and Pascal Zufferey⁶, ¹gastroenterology, Lausanne, Switzerland, ²DAL, RHU, Lausanne, Switzerland, ³DAL, MPR, Lausanne, Switzerland, ⁴Medecine /CHUV, Immunology, Lausanne, Switzerland, ⁵La Source-Beaulieu, Lausanne, Switzerland, ⁶Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland
Background/Purpose: Infliximab is a biological agent frequently used for inflammatory arthritis (IA) such as spondyloarthritis, rheumatoid arthritis, psoriatic arthritis as well as for the inflammatory…
Abstract Number: 2905 • 2016 ACR/ARHP Annual Meeting
Predictors of Poor Hand Function in Systemic Sclerosis
Ashraf Raslan¹ and Vivien Hsu², ¹Medicine, Rutgers-RWJ Medical School, Jersey City, NJ, ²Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ
Background/Purpose: Systemic Sclerosis (SSc) is a progressive systemic disease that can lead to variable degrees of morbidity and disability. Hand dysfunction in SSc patients [1]…
Abstract Number: 830 • 2016 ACR/ARHP Annual Meeting
Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort
Anna Hoffmann-Vold¹, Anders Heiervang Tennøe², Oyvind Midtvedt², May Brit Lund³, Torhild Garen², Fadi El-Hage⁴, Trond Mogens Aalokken⁵, Eli Taraldsrud⁴ and Øyvind Molberg², ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵Radiology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Extensive skin disease and renal crisis are hallmarks of anti-RNA polymerase III (RNAP) positive systemic sclerosis (SSc), while data on lung and heart involvement…
Abstract Number: 3225 • 2016 ACR/ARHP Annual Meeting
Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis
Mark C. Genovese¹, Michael Weinblatt², Heikki T. Mansikka³, Paul M. Peloso³, Kun Chen³, Yihan Li³, John Liu³ and Robert J. Padley³, ¹Stanford University Medical Center, Palo Alto, CA, ²Brigham and Women’s Hospital, Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: ABT-122 is a dual variable domain immunoglobulin (DVD-Ig™) that targets human tumor necrosis factor-α (TNF-α) and interleukin-17A (IL-17A). The object was to investigate the…
Abstract Number: 2019 • 2015 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammatory Arthritis in First Degree Relatives of Patients with Rheumatoid Arthritis and Their Association with Lifestyle Risk Factors
Jamie C Sergeant and RA-MAP Consortium, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP) and C-reactive protein (CRP) are known serum biomarkers of inflammatory arthritis (IA) and have potential predictive…
Abstract Number: 2057 • 2015 ACR/ARHP Annual Meeting
Antibodies to Infliximab in Remicade-Treated Rheumatic Patients Show Identical Reactivity Towards Biosimilars
Begoña Ruiz-Argüello¹, Ainara Maguregui¹, Ainhoa Ruiz del Agua¹, Dora Pascual-Salcedo², Ana Martínez², Teresa Jurado³, Chamaida Plasencia⁴, Alejandro Balsa⁵, Francisca Llinares-Tello⁶, José Rosas⁷, Nerea Torres¹, Antonio Martínez¹ and Daniel Nagore¹, ¹R&D, Progenika-Grifols, Derio, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁶Clinical Analysis, Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain, ⁷Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain
Background/Purpose: Infliximab (IFX) is the most immunogenic of anti-TNFα drugs available to treat patients with rheumatic diseases. The recent approval of the first infliximab biosimilars in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].